乐观
$59.37
情景价格
$68.270
+1.243 (+1.82%)收盘时
Centene Corporation is a healthcare company. It provides access to quality healthcare; programs and a range of health solutions that help families and individuals get well. Its segments include Medicaid, Medicare, Commercial and Other. The Medicaid segment includes the Temporary Assistance for Needy Families (TANF) program, Medicaid Expansion programs, the Aged, Blind or Disabled (ABD) program, the Children's Health Insurance Program (CHIP), Long-Term Services and Supports (LTSS), Foster Care, Medicare-Medicaid Plans (MMP), which cover beneficiaries who are dually eligible for Medicaid and Medicare and other state-based programs. The Medicare segment includes Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans and Medicare Prescription Drug Plans. The Commercial segment includes the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products.
Centene Corp is a good buy right now, as it is currently priced at $70.17, with a forward P/E ratio of 11.59, indicating potential for growth. The stock has shown a year-to-date change of +67.95% and a 1-year change of +111.67%, reflecting strong upward momentum. Additionally, analysts have set a price target of $80, suggesting a potential upside of approximately 14% from the current price. However, investors should be cautious of the recent net income fluctuations, particularly the significant loss of -6.63 per share in Q3 2025, which highlights volatility in earnings.
JPMorgan
$75
2026-10-29
JPMorgan
2026-10-29
目标价
$75
Baird
$71
2026-10-28
Baird
2026-10-28
目标价
$71
Mizuho
$72
2026-10-28
Mizuho
2026-10-28
目标价
$72
Morgan Stanley
$71
2026-10-28
Morgan Stanley
2026-10-28
目标价
$71
Cantor Fitzgerald
$79
2026-10-28
Cantor Fitzgerald
2026-10-28
目标价
$79
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Centene Surpasses Q3 Estimates, Raises 2026 Earnings Guidance

Centene Reports Q3 Earnings Beat with Adjusted EPS of $0.58

Market Confidence Rebuilds as AI Trade Recovers

Ambetter Health Introduces New Heart Failure Coverage and Expands Chronic Care Solutions

Ambetter Health Introduces New Heart Failure Coverage and Expands Chronic Care Solutions
Centene Corporation is a healthcare company. It provides access to quality healthcare; programs and a range of health solutions that help families and individuals get well. Its segments include Medicaid, Medicare, Commercial and Other. The Medicaid segment includes the Temporary Assistance for Needy Families (TANF) program, Medicaid Expansion programs, the Aged, Blind or Disabled (ABD) program, the Children's Health Insurance Program (CHIP), Long-Term Services and Supports (LTSS), Foster Care, Medicare-Medicaid Plans (MMP), which cover beneficiaries who are dually eligible for Medicaid and Medicare and other state-based programs. The Medicare segment includes Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans and Medicare Prescription Drug Plans. The Commercial segment includes the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).
Centene Corp is a good buy right now, as it is currently priced at $70.17, with a forward P/E ratio of 11.59, indicating potential for growth. The stock has shown a year-to-date change of +67.95% and a 1-year change of +111.67%, reflecting strong upward momentum. Additionally, analysts have set a price target of $80, suggesting a potential upside of approximately 14% from the current price. However, investors should be cautious of the recent net income fluctuations, particularly the significant loss of -6.63 per share in Q3 2025, which highlights volatility in earnings.
17 analysts cover CNC: 12 rate it Buy, 5 Hold and 0 Sell. The average price target is 43.07.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。